KYP-2047
Cat. No.：YN270777
| 产品名称: | KYP-2047 |
| CAS No.: | 796874-99-2 |
| Chemical Name: | |
| Synonyms: | (2s)-1-[1-(4-Phenylbutanoyl)-L-Prolyl]pyrrolidine-2-Carbonitrile;4an0;KYP 2047;BDBM50155838;4-phenylbutanoyl-l-prolyl-2(s)-cyanopyrrolidine;Q27453163;(2S)-1-[[(2S)-1-(1-Oxo-4-phenylbutyl)-2-pyrrolidinyl]carbonyl]-2-pyrrolidinecarbonitrile;(S)-1-((S)-1-(4- |
| 分子量: | 339.431404829025 |
| 分子式: | C20H25N3O2 |
| SMILES: | O=C([C@]1([H])C([H])([H])C([H])([H])C([H])([H])N1C(C([H])([H])C([H])([H])C([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H])=O)N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C#N |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | KYP-2047 是一种有效的可透过血脑屏障的脯氨酸寡肽酶 (POP) 抑制剂，其 Ki值为 0.023 nM。KYP-2047 通过血管生成和凋亡调节来减少胶质母细胞瘤的增殖。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
